Trust Investment Advisors Has $650,000 Stock Position in Danaher Co. (NYSE:DHR)

Trust Investment Advisors lifted its position in shares of Danaher Co. (NYSE:DHR) by 1.8% during the fourth quarter, Holdings Channel.com reports. The firm owned 2,811 shares of the conglomerate’s stock after purchasing an additional 49 shares during the period. Trust Investment Advisors’ holdings in Danaher were worth $650,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the business. Calamos Advisors LLC lifted its position in shares of Danaher by 36.2% during the 4th quarter. Calamos Advisors LLC now owns 329,902 shares of the conglomerate’s stock valued at $76,320,000 after buying an additional 87,658 shares during the last quarter. Xponance Inc. lifted its holdings in Danaher by 9.6% during the fourth quarter. Xponance Inc. now owns 94,101 shares of the conglomerate’s stock valued at $21,769,000 after purchasing an additional 8,252 shares during the last quarter. AIA Group Ltd boosted its position in Danaher by 614.2% during the fourth quarter. AIA Group Ltd now owns 153,827 shares of the conglomerate’s stock worth $35,586,000 after purchasing an additional 132,289 shares during the period. SFE Investment Counsel increased its stake in shares of Danaher by 40.7% in the fourth quarter. SFE Investment Counsel now owns 12,670 shares of the conglomerate’s stock worth $2,931,000 after purchasing an additional 3,665 shares in the last quarter. Finally, Cambridge Trust Co. lifted its stake in shares of Danaher by 1.7% during the 4th quarter. Cambridge Trust Co. now owns 74,438 shares of the conglomerate’s stock valued at $17,221,000 after buying an additional 1,233 shares in the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, SVP Daniel Raskas sold 23,757 shares of the business’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $252.00, for a total transaction of $5,986,764.00. Following the completion of the transaction, the senior vice president now owns 38,102 shares of the company’s stock, valued at $9,601,704. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, SVP Daniel Raskas sold 23,757 shares of the business’s stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $252.00, for a total transaction of $5,986,764.00. Following the sale, the senior vice president now owns 38,102 shares of the company’s stock, valued at $9,601,704. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Teri List sold 3,289 shares of Danaher stock in a transaction that occurred on Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total transaction of $816,724.48. Following the completion of the transaction, the director now directly owns 19,726 shares in the company, valued at $4,898,360.32. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 32,957 shares of company stock worth $8,265,802. 11.10% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on DHR. HSBC upgraded shares of Danaher from a “hold” rating to a “buy” rating and lifted their price objective for the company from $250.00 to $280.00 in a research note on Wednesday. Royal Bank of Canada increased their price objective on Danaher from $254.00 to $282.00 and gave the stock an “outperform” rating in a report on Wednesday, January 31st. JPMorgan Chase & Co. lifted their target price on Danaher from $250.00 to $270.00 and gave the company an “overweight” rating in a report on Wednesday, December 20th. Citigroup increased their price target on shares of Danaher from $255.00 to $280.00 and gave the stock a “buy” rating in a report on Wednesday, January 31st. Finally, Raymond James upped their target price on shares of Danaher from $240.00 to $270.00 and gave the stock an “outperform” rating in a report on Wednesday, January 31st. Six equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, Danaher has a consensus rating of “Moderate Buy” and a consensus target price of $268.27.

Danaher Trading Down 1.3 %

Shares of DHR traded down $3.03 during midday trading on Thursday, hitting $236.36. The stock had a trading volume of 4,235,840 shares, compared to its average volume of 2,727,856. The stock’s 50 day moving average is $249.28 and its 200 day moving average is $229.86. The firm has a market cap of $175.03 billion, a PE ratio of 37.46, a price-to-earnings-growth ratio of 3.65 and a beta of 0.83. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.68 and a quick ratio of 1.37. Danaher Co. has a 1 year low of $182.09 and a 1 year high of $259.00.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, January 30th. The conglomerate reported $2.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.91 by $0.18. The firm had revenue of $6.41 billion for the quarter, compared to analyst estimates of $6.10 billion. Danaher had a return on equity of 12.25% and a net margin of 17.26%. Danaher’s revenue was down 10.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.87 EPS. As a group, analysts forecast that Danaher Co. will post 7.62 EPS for the current fiscal year.

Danaher Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 26th. Investors of record on Thursday, March 28th will be issued a dividend of $0.27 per share. This is a positive change from Danaher’s previous quarterly dividend of $0.24. The ex-dividend date is Wednesday, March 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.46%. Danaher’s payout ratio is presently 16.90%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.